Aspyre® Clinical Test for Lung: a rapid alternative to Comprehensive Genomic Profiling
Hear experts address the gaps and limitations of CGP by using innovative simplified genomic profiling solutions that work for challenging samples not analyzable by CGP.
Beyond ALK & EGFR: Shifting the treatment paradigm of early-stage NSCLC
A new study from Biofidelity is examining how its Aspyre technology can bridge the gaps in clinical care that prevent early-stage NSCLC patients from receiving molecular profiling.
Our certificate has been awarded for the design and development of reagents and consumables for use with in vitro diagnostic assays for molecular testing.
Introducing Aspyre Clinical Test: A breakthrough in lung cancer testing
Discover Aspyre Clinical Test, a breakthrough in lung cancer testing. Our technology provides physicians with actionable results within days of diagnosis, enabling rapid identification of the best treatment options.
Biomarker and sequential testing in early stages of NSCLC are emerging testing paradigms
Learn about the emerging trends in biomarker testing for early-stage non-small cell lung cancer (NSCLC) and the impact of minimal residual disease (MRD) testing.
The 2023 ASCO meeting showcased impressive clinical advances in cancer treatment, but a study on liquid biopsy technology raises questions about false positive results and clinical management. Is this good enough for patients?
Complexity of NGS-based biomarker testing and contemporary genomic biomarker testing rates reveal persistent gaps in NSCLC patient care
Biofidelity's VP of Strategic Marketing, Anjana Bhattacharya, shares her thoughts from ASCO 2023 on how the complexity of NGS-based biomarker testing and contemporary genomic biomarker testing rates reveal persistent gaps in NSCLC patient care.